BioAffinity Technologies Inc. (BIAF)
NASDAQ (CM) NASDAQ (CM) Primary 
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies Inc (NASDAQ: BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung diagnostic, even as total revenue declined following a strategic shift away from lower-margin lab services. Here's what investors need to know.
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead?
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth
bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation
Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges.
